Brief: Rocket Pharmaceuticals Reaches FDA Alignment On Pivotal Phase 2 Trial Design For Rp-A501 In Danon Disease

Rocket Pharmaceuticals

12/09/2023 22:27

Rocket Pharmaceuticals Inc  RCKT.O :
    * ROCKET PHARMACEUTICALS REACHES FDA ALIGNMENT ON PIVOTAL
PHASE 2
TRIAL DESIGN FOR RP-A501 IN DANON DISEASE
    * ROCKET PHARMACEUTICALS INC - CO-PRIMARY ENDPOINT
CONSISTING OF
LAMP2 PROTEIN EXPRESSION AND LEFT VENTRICULAR (LV) MASS CHANGE
FROM BASELINE
    * ROCKET PHARMACEUTICALS INC: CO-PRIMARY ENDPOINT CONSISTING
OF
LAMP2 PROTEIN EXPRESSION AND LEFT VENTRICULAR (LV) MASS CHANGE
FROM BASELINE
    * ROCKET PHARMACEUTICALS - FILING OF CTA/ IMPD FOR RP-A501
TO
ENABLE INITIATION OF EU STUDY ACTIVITIES IS ANTICIPATED IN Q3 OF
THIS YEAR

Source text for Eikon:  ID:nBw2tVZsha 
Further company coverage:  RCKT.O